abstract |
The present invention relates to a novel crystalline form of dopopidine, a drug substance currently under development for the treatment of Huntington's disease. More specifically, the invention relates to polymorphic form II of dopedine hydrochloride salt, a process for preparing such a polymorphic form, pharmaceutical compositions containing polymorphic form II, and methods for using such a polymorphic form. |